| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10005436 | HBV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS10019441 | HBV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS10048786 | HBV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS30079989 | HIV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS30077211 | HIV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS30072378 | HIV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS20015392 | HPV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS20067885 | HPV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS20015235 | HPV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS20015236 | HPV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | RXRA |
|---|---|
| DrugBank ID | DB00523 |
| Drug Name | Alitretinoin |
| Target ID | BE0000412 |
| UniProt ID | P19793 |
| Regulation Type | agonist |
| PubMed IDs | 16428452; 16751185; 16782282; 16819260; 16946489; 18321241; 19678713 |
| Citations | Bartholin L, Powers SE, Melhuish TA, Lasse S, Weinstein M, Wotton D: TGIF inhibits retinoid signaling. Mol Cell Biol. 2006 Feb;26(3):990-1001.@@Calleja C, Messaddeq N, Chapellier B, Yang H, Krezel W, Li M, Metzger D, Mascrez B, Ohta K, Kagechika H, Endo Y, Mark M, Ghyselinck NB, Chambon P: Genetic and pharmacological evidence that a retinoic acid cannot be the RXR-activating ligand in mouse epidermis keratinocytes. Genes Dev. 2006 Jun 1;20(11):1525-38.@@Zhelyaznik N, Mey J: Regulation of retinoic acid receptors alpha, beta and retinoid X receptor alpha after sciatic nerve injury. Neuroscience. 2006 Sep 15;141(4):1761-74. Epub 2006 Jun 19.@@Fukasawa H, Kagechika H, Shudo K: [Retinoid therapy for autoimmune diseases]. Nihon Rinsho Meneki Gakkai Kaishi. 2006 Jun;29(3):114-26.@@Mizuguchi Y, Wada A, Nakagawa K, Ito M, Okano T: Antitumoral activity of 13-demethyl or 13-substituted analogues of all-trans retinoic acid and 9-cis retinoic acid in the human myeloid leukemia cell line HL-60. Biol Pharm Bull. 2006 Sep;29(9):1803-9.@@Cheng C, Michaels J, Scheinfeld N: Alitretinoin: a comprehensive review. Expert Opin Investig Drugs. 2008 Mar;17(3):437-43. doi: 10.1517/13543784.17.3.437 .@@Garnock-Jones KP, Perry CM: Alitretinoin: in severe chronic hand eczema. Drugs. 2009 Aug 20;69(12):1625-34. doi: 10.2165/11202200-000000000-00000. |
| Groups | Approved; Investigational |
| Direct Classification | Retinoids |
| SMILES | CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O |
| Pathways | Retinol Metabolism; Vitamin A Deficiency |
| PharmGKB | PA164746900 |
| ChEMBL | CHEMBL705 |
